Literature DB >> 3014535

Topoisomerase I identified by scleroderma 70 antisera: enrichment of topoisomerase I at the centromere in mouse mitotic cells before anaphase.

G G Maul, B T French, W J van Venrooij, S A Jimenez.   

Abstract

Antibodies derived from scleroderma patients positive for the extractable 70-kDa antigen were shown to react with topoisomerase I. Topoisomerase I was identified by molecular size and by antibody inhibition of the topoisomerase I-specific relaxation of supercoiled plasmid DNA. By using in situ localization by indirect fluorescence, we found topoisomerase I preferentially located in the centromeric regions of the mouse G2-phase cells and chromosomes, while the distribution in human cells is much more dispersed. Moreover, comparison of a published consensus sequence for topoisomerase I binding with mouse satellite DNA revealed a high degree of homology. The localization of topoisomerase I in the centromeres of mouse cells in the later part of the cell cycle and prior to anaphase suggests functional involvement in mitosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3014535      PMCID: PMC323907          DOI: 10.1073/pnas.83.14.5145

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  High resolution two-dimensional electrophoresis of basic as well as acidic proteins.

Authors:  P Z O'Farrell; H M Goodman; P H O'Farrell
Journal:  Cell       Date:  1977-12       Impact factor: 41.582

2.  Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma.

Authors:  A S Douvas; M Achten; E M Tan
Journal:  J Biol Chem       Date:  1979-10-25       Impact factor: 5.157

3.  Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei.

Authors:  L F Liu; K G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

4.  Phosphorylation of purified Novikoff hepatoma topoisomerase I.

Authors:  E Durban; J S Mills; D Roll; H Busch
Journal:  Biochem Biophys Res Commun       Date:  1983-03-29       Impact factor: 3.575

5.  High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients.

Authors:  J H Shero; B Bordwell; N F Rothfield; W C Earnshaw
Journal:  Science       Date:  1986-02-14       Impact factor: 47.728

6.  Autoantibody to centromere (kinetochore) in scleroderma sera.

Authors:  Y Moroi; C Peebles; M J Fritzler; J Steigerwald; E M Tan
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

7.  The CREST syndrome: a distinct serologic entity with anticentromere antibodies.

Authors:  M J Fritzler; T D Kinsella
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

8.  Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome.

Authors:  E M Tan; G P Rodnan; I Garcia; Y Moroi; M J Fritzler; C Peebles
Journal:  Arthritis Rheum       Date:  1980-06

9.  Topoisomerase I from chicken erythrocytes: purification, characterization, and detection by a deoxyribonucleic acid binding assay.

Authors:  J V Tricoli; D Kowalski
Journal:  Biochemistry       Date:  1983-04-12       Impact factor: 3.162

10.  Kinetochore structure, duplication, and distribution in mammalian cells: analysis by human autoantibodies from scleroderma patients.

Authors:  S Brenner; D Pepper; M W Berns; E Tan; B R Brinkley
Journal:  J Cell Biol       Date:  1981-10       Impact factor: 10.539

View more
  19 in total

Review 1.  B-cell epitopes of scleroderma-specific autoantigens.

Authors:  R Verheijen
Journal:  Mol Biol Rep       Date:  1992-06       Impact factor: 2.316

2.  IgM, IgG, and IgA anti-DNA topoisomerase I antibodies in systemic sclerosis.

Authors:  Erasmo Martínez-Cordero; Alejandro Padilla Trejo; Diana E Aguilar León
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

3.  A nucleolar auto-antigen is part of a major chromosomal surface component.

Authors:  Y Yasuda; G G Maul
Journal:  Chromosoma       Date:  1990-04       Impact factor: 4.316

4.  Antikinetochore and antitopoisomerase I antibodies in systemic scleroderma: comparative study using immunoblotted recombinant antigens, immunofluorescence, and double immunodiffusion.

Authors:  M Jarzabek-Chorzelska; M Blaszczyk; Z Kolacinska-Strasz; T Chorzelski; S Jabłońska; G G Maul
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

Review 5.  Antitopoisomerase and anticentromere antibodies in the sclerodermatosus complex.

Authors:  C G Kallenberg
Journal:  Clin Rev Allergy       Date:  1994

6.  Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I: sequence similarity with retroviral p30gag protein suggests a possible cause for autoimmunity in systemic sclerosis.

Authors:  G G Maul; S A Jimenez; E Riggs; D Ziemnicka-Kotula
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

7.  A recombinant topoisomerase I used for autoantibody detection in sera from patients with systemic sclerosis.

Authors:  R Verheijen; F Van den Hoogen; R Beijer; A Richter; E Penner; W J Habets; W J van Venrooij
Journal:  Clin Exp Immunol       Date:  1990-04       Impact factor: 4.330

8.  Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting.

Authors:  C G Kallenberg; A A Wouda; M H Hoet; W J van Venrooij
Journal:  Ann Rheum Dis       Date:  1988-08       Impact factor: 19.103

9.  Antibodies against Ku protein in sera from patients with autoimmune diseases.

Authors:  M Yaneva; F C Arnett
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

10.  A recombinant topoisomerase I ELISA: screening for IgG, IgM and IgA anti-topo I autoantibodies in human sera.

Authors:  R Verheijen; B A de Jong; W J van Venrooij
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.